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https://doi.org/10.1186/s12969-019-0377-7RESEARCH ARTICLE Open AccessCan quantitative MRI be used in the clinical
setting to quantify the impact of intra-
articular glucocorticoid injection on
synovial disease activity in juvenile
idiopathic arthritis?
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S. Claire Gowdy5, Helen E. Foster1,2, Flora McErlane1,2† and Kieren G. Hollingsworth6*†Abstract
Background: Juvenile idiopathic arthritis (JIA), the most common chronic rheumatic disease of childhood, is
characterised by synovitis. Clinical assessments of synovitis are imperfect, relying on composite and indirect
measures of disease activity including clinician-reported measures, patient-reported measures and blood markers.
Contrast-enhanced MRI is a more sensitive synovitis assessment technique but clinical utility is currently limited by
availability and inter-observer variation. Improved quantitative MRI techniques may enable future development of
more stringent MRI-defined remission criteria.
The objective of this study was to determine the utility and feasibility of quantitative MRI measurement of synovial
volume and vascularity in JIA before and twelve weeks after intra-articular glucocorticoid injection (IAGI) of the knee
and to assess the acceptability of MRI to participating families.
Methods: Children and young people with JIA and a new episode of knee synovitis requiring IAGI were recruited
from the Great North Children’s Hospital in Newcastle upon Tyne. Quantitative contrast-enhanced MRI was
performed prior to and twelve weeks after IAGI, in addition to standard clinical assessment tools, including the
three-variable clinical juvenile arthritis disease activity score (cJADAS) and active joint count.
Results: Eleven young people (5 male, median age 13 years, range 7–16) with JIA knee flare were recruited and 10
completed follow-up assessment. Following IAGI, the median (interquartile range) cJADAS improved from 8.5 (2.7)
to 1.6 (3.9), whilst the median synovial volume improved from 38.5cm3 (82.1cm3) to 0.0cm3 (0.2cm3). Six patients
presented with frank synovitis outside normal limits on routine MRI reporting. A further three had baseline MRI
reports within normal limits but the quantitative measurements identified measurable synovial uptake. Post-IAGI
quantitative measurements highlighted significant improvements in 9 patients.
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Conclusions: IAGI led to a marked reduction in synovial volume, with quantitative MRI identifying more patients
with an improved synovial volume than routine qualitative clinical reporting. Improvements in cJADAS scores were
more variable with the patient/parent global assessment component contributing most to the scores. Further work
is indicated, exploring the utility of quantitative MRI in the assessment of less accessible joints and comparing the
impact of different treatment modalities.
Keywords: Juvenile idiopathic arthritis, Disease activity assessment, Quantitative MRI, Synovitis, Synovial volume,
Intra-articular glucocorticoid injection, RemissionBackground
Juvenile idiopathic arthritis (JIA) is an umbrella term,
summarising the International League of Associations for
Rheumatology (ILAR) classification system for the mark-
edly heterogeneous chronic idiopathic paediatric arthriti-
des [1, 2]. JIA is the most common chronic rheumatic
disease in children and young people with a UK preva-
lence of 1:1000 [3]. Affected joints are characterised by
synovial proliferation and inflammatory cell infiltration,
resulting in synovial effusion and hypertrophy.
JIA is a relapsing and remitting condition and the majority
of young people will have more than one inflammatory flare
during the two years following initial diagnosis. At least one-
third of young people continue to have episodes of active
inflammation during their adult years [4]. Long-standing
poorly controlled synovitis is associated with a high fre-
quency of joint damage and joint replacement surgery in
adults with JIA [5]. Early aggressive therapy, including
intraarticular glucocorticoid injection (IAGI) and prompt
introduction of systemic immunosuppression, is thought to
improve remission rates, prevent joint damage and improve
functional outcomes in JIA [6]. IAGI induces rapid suppres-
sion of inflammation in targeted joints through a complex
combination of effects including reduced leucocyte cell
infiltration, altered leucocyte activity, reduced synovial perfu-
sion and reduced vascular permeability [7, 8].
The heterogeneous nature of JIA and normal develop-
mental changes of childhood ensure that no single
clinical assessment can reliably capture overall disease
activity in all young people with JIA [9]. At the present
time, clinicians rely on composite measures of disease
activity, comprising multiple indirect clinical and blood
markers, including the active and limited joint counts
(AJC / LJC), disability score (CHAQ) [10], ESR/CRP and
global assessments by clinicians and parents. None of
these accurately reflects the synovial state, and many are
subjective in nature with limited repeatability [11]. JIA-
specific composite tools have been used to derive
multiple definitions of remission and it is not yet clear
which, if any, constitutes the optimal definition [12].
The lack of a single ‘gold standard’ treatment target is
one of the central barriers to implementing modern
treat-to-target regimes in clinical practice [13].Newer imaging modalities, such as musculoskeletal
ultrasound (MSUS) and magnetic resonance imaging
(MRI), have the potential to further inform our under-
standing of remission in JIA. Comparison of clinical and
imaging-based definitions of remission is considered a
high priority for future research [14].
Ultrasound (US) and colour Doppler techniques can
detect subclinical synovitis in young people with JIA,
and there have been extensive efforts in recent years to
define the normal US appearance of paediatric joints
[15], to create definitions for the sonographic features of
synovitis in young people [16], and to standardise acqui-
sition protocols and scoring systems [17]. Although this
work is important, paediatric MSUS requires specialist
skills and training and may not be available at all cen-
tres. Furthermore, the non-uniform accessibility of many
joint spaces limits MSUS scoring to broad grades [18].
Contrast-enhanced MRI is able to visualise the syno-
vitis that drives the degradative disease process, even at
low levels, and is recognised to be the most sensitive
technique for the assessment of synovitis [19–21]. Post-
contrast T1-weighted images clearly differentiate the
extent of synovial hypertrophy vs. free fluid in the joint.
In fact, MRI can identify synovial changes indicative of
active disease in young people with JIA who fulfil clinical
criteria for inactive disease [22]. Unenhanced MRI can
uniquely detect bone oedema in addition to bone ero-
sions. However, the clinical utility of MRI has been
modest due to availability and the acceptability of MRI
scanning in paediatric populations. While there has been
research activity demonstrating the potential of MRI in
the assessment of intra-articular disease activity, there
are limited normative paediatric data, recruited cohorts
have had mixed presentations and there is a lack of JIA-
specific clinical assessment tools to validate the findings.
Consequently, there is wide inter-observer variation in
the interpretation and reporting of MRI scans.
In clinical practice, synovial enhancement is reported
as either being within or exceeding normal limits, based
on an expected normal appearance. In research, the
qualitative JAMRIS score (juvenile arthritis MRI scoring
system) has been proposed as a classification of synovial
hypertrophy on a 3-point scale (< 2 mm, 2-4 mm or > 4
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insensitive to longitudinal change [23, 24]. By contrast,
we can seek to quantify properties of disease activity on
continuous scales by image processing, rather than
qualitative description or grading. The potential advan-
tage of such an approach is the ability to discriminate
change more finely than qualitative scales, and to meas-
ure disease activity that may fall below present qualita-
tive reporting standards [25–27]. The cost of such
approaches is the analysis effort required.
In summary, quantitative MRI may have considerable
utility in both clinical research and the clinical care of
young people with JIA, since it can provide sensitive,
continuous measurement of synovial volume and the
vascularity of the synovium through dynamic measure-
ment of the uptake of gadolinium contrast agent. This
study investigates whether quantitative MRI can provide
a sensitive measurement of the effects of IAGI in young
people with JIA, and compares synovial volume and
contrast uptake measurements. The study also assesses
the feasibility and acceptability of the imaging for chil-
dren and parents through feedback by questionnaire and
telephone interviews.
Methods
Subjects
Young people were recruited from a tertiary paediatric
rheumatology service in the North of England (The
Great North Children’s Hospital at Newcastle upon
Tyne Hospitals NHS Foundation Trust). Patients and
their families attending clinic were invited to consider
participating in the study if all inclusion criteria were
present (new or known diagnosis of JIA, new presenta-
tion of knee synovitis requiring intra-articular gluco-
corticoid injection (IAGI) and age 4–16 years). Exclusion
criteria were steroid injection of involved knee in the
past six months, concurrent use of oral or IV steroids,
contraindications to contrast agent or non-sedated MRI,
non-English speaking families, or recent trauma to the
knee. No changes were made to concomitant immuno-
suppressive treatments during the study period. Families
of young people who were eligible and interested at their
clinic visit were followed up by telephone and invited to
take part in the study.
Additional file 1: Fig. S1 shows the recruitment flow
chart for the study. The subjects had two MRI and
clinical assessments, the first prior to the intra-articular
injection and the second at least twelve weeks after the
injection. Affected knees were injected with 1 mg/kg tri-
amcinolone hexacetonide to a maximum of 40 or 60 mg
depending on weight: image guidance was not used, as
per local protocol. Where both knees were affected, both
were injected, and the knee judged most affected at clin-
ical examination was followed by MRI. The study,performed between September 2017 and August 2018,
complied with the Declaration of Helsinki and obtained
a favourable opinion from the Newcastle and North
Tyneside 1 Research Ethics Committee and the Health
Research Authority, with the parents/carers of the sub-
jects giving written informed consent, and written assent
from the young people. Routine clinical care was not al-
tered by the addition of the MRI scanning. KGH had
control of the study data and had responsibility for over-
seeing data acquisition and processing.Clinical assessments
Clinical assessment was performed at baseline and
follow-up. This included measurement of the core out-
come variables: binary 74-joint active and limited joint
counts, physician global score of disease activity (10 cm
visual analogue scale (VAS)), patient/parent global score
of disease activity (10 cm VAS), CHAQ and ESR/CRP
(where available) [28], a global pain score (10 cm VAS)
and the 3 and 4 variable juvenile arthritis disease activity
scores (cJADAS and JADAS) [29, 30]. Clinical remission
was defined according to the JADAS and cJADAS cut-
offs for inactive disease (</= 1) [31, 32].
MRI protocol
A peripheral venous cannula was inserted in the upper
limb. Subjects were made comfortable in a supine feet-first
orientation on a Siemens 1.5 T Espree, using an extremity
birdcage coil. The MRI sequences (including T2-, T1- and
proton density weighted scans, Additional file 1: Table S1)
were prescribed so that the bottom slice passed through
the proximal aspect of the superior tibiofibular joint. The
leg position and anatomical location were carefully
matched at the post-treatment visit. The sequences in-
cluded pre- and post-contrast T1-weighted (T1w) imaging
to distinguish synovial enhancement and a multiple dy-
namic T1w sequence was used to collect dynamic gadolin-
ium uptake data before, during and after the injection of
contrast agent. After two dynamics (26 s), the contrast
agent was administered by hand as a standard single dose
of gadoterate meglumine (Dotarem, 0.2 ml/kg body weight,
Guerbet), followed by a 3ml flush of 0.9% sodium chloride.
The uptake of contrast was imaged for five minutes post-
injection. The post-contrast T1w fat suppressed turbo spin
echo imaging was collected immediately after the dynamic
series ended such that post-contrast data were collected 5
min post injection as recommended [33].
Image processing
The MRI images were reported by a consultant radiologist
(JDT) and were also quantitatively processed using custom
software in MATLAB 2017a (Mathworks, UK) and ImageJ
v1.43u (NIH, USA). The images of the dynamic gradient
Fig. 1 Procedure for calculating the synovial volume, shown on one
slice of the imaged knee volume. The acquired data are (a) the
multi-slice T1-weighted FS TSE pre-contrast and (b) post-contrast
showing synovial hypertrophy. (c) These image stacks are subtracted
to produce a stack of difference images which highlight the signal
change caused by contrast uptake compared to other tissues; (d)
thresholding these values helps to segment the enhancing
synovium from structures with low uptake, though blood vessels
remain visible. The magic wand tool of ImageJ is used to select the
enhancing synovium; the volume is calculated by summing across
the image stack. FS TSE, fat saturated turbo spin echo
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registered to the pre-contrast T1w sequence to eliminate
the effect of minor subject movement during the scan. A
difference image stack was formed by subtracting the
image intensity of the pre-contrast T1w sequence (Fig. 1a)
from the post-contrast (Fig. 1b) to highlight the intensity of
gadolinium uptake (Fig. 1c). This difference image was
thresholded and binary gated to allow semi-automated de-
lineation of the enhancing synovium from adjacent tissues
throughout the imaging volume (Fig. 1d): the synovial
volume was calculated from this by automatically summing
the areas from each slice and multiplying by the slice thick-
ness (see Additional file 1: for further detail). The signal
increase due to contrast agent entering the synovium was
expressed as a percentage increase compared to the first
four dynamics before the gadolinium arrived (Fig. 2). Using
the delineation of the synovium, the initial rate of uptake
was estimated (in %/s) from the gradient of the first two
measurements after the arrival of contrast (Fig. 2). The
signal enhancement (in %) was calculated as the mean per-
centage increase of the final four dynamics of the series
(Fig. 2, see Additional file 1 for further detail). Quantitative
analysis was performed by two observers working inde-
pendently (KGH, an MRI physicist with 12 years’ experi-
ence in MSK imaging, and JLB, a specialist trainee in
paediatrics).
Patient acceptability questionnaires and telephone
feedback
To assess the acceptability of our research protocol, we
asked the families to provide feedback in two ways. At
the end of the first MRI appointment, young people and
their families were invited to complete a NHS England
‘Friends and Family’ questionnaire [34] and this was
followed up with a telephone interview in which the
families were asked to discuss their experience of the
MRI visit in more detail. The topics presented in this
telephone interview and the formal analysis methods
used are given in Additional file 1.
Time occupation of the scanner suite, and study subject
time
For all MRI sessions, scan timings were extracted from
the DICOM headers. Where feasible, the total time
between the families arriving and leaving the MRI unit
was measured.
Statistical analysis
Data were analysed in SPSS version 24 (RSI, Boulder)
and expressed as median (interquartile range, IQR) ex-
cept where medians and ranges have been explicitly
stated. The changes in synovial volume, initial rate of
contrast uptake and signal enhancement between the
baseline and follow-up visits, AJC, cJADAS and painglobal score were analysed with the non-parametric
Wilcoxon signed-rank test. The inter-observer agree-
ment was assessed by using Bland-Altman analysis [35].
The bias and 95% limits of agreement was calculated be-
tween the two observers. Association between synovial
volumes and clinical assessments was performed using
the Spearman’s rank test.Results
Eleven young people (5 male; 6 female; median age 13.4
years; age range 7.7–16.0) participated successfully in
the baseline studies. Demographic and clinical data
(including concomitant medication) are presented in
Table 1. Ten young people attended and successfully
completed the second MRI research visits: contact with
one family was lost and follow-up data could not be col-
lected. Only one family approached with study informa-
tion declined to take part in the research.
The median time between initial clinic visit and first
MRI assessment was 7 days (range 6–8 days). IAGI was
usually performed later the same day (median 0 days
after initial MRI, range 0–21 days). The median time
from joint injection to the second MRI and clinical
Fig. 2 Percentage gadolinium signal increase across the segmented synovial volume for subject 5. The contrast is injected at the time shown in
the arrow. The initial uptake rate (%/s) is calculated from the gradient of the line of the first two positive signal increases and the signal
enhancement (%) is the mean of the last four points. This subject had a change in synovial volume from 72.2cm3 pre-treatment to 0.7cm3 post-
treatment. The initial uptake shown reduces from 2.83%/s to 0.51%/s post-treatment and signal enhancement reduces from 190 to 90%
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weeks). The time required for subjects’ MRI appoint-
ments is presented in the Additional file 1.
The median time (IQR) for contrast to reach the syno-
vium after the beginning of the scan was 63 (14) seconds
and contrast never reached synovium before the fifth
image (range fifth-seventh image). Therefore, the uptake
of gadolinium was followed for a median time of 315
(14) seconds after injection.
Clinical assessments
Baseline and follow-up clinical assessments are pre-
sented in Table 1 and Fig. 3. Clinician-assessed disease
activity in the injected knee changed from present to ab-
sent in 7/10 participants post-IAGI. Two of the three
participants with persisting clinician-assessed disease ac-
tivity had a measurable synovial volume on follow-up
MRI; one did not. All three participants with persisting
clinically-assessed disease activity had repeat IAGI. This
subsequently led to clinical improvement in the two with
a measurable synovial volume and no improvement in
the third young person. Although the AJC decreased sig-
nificantly overall, it did not change in 4/10 patients. The
physician global score reduced after joint injection in all
cases, as did the parent global score for 9/10 cases.
Where the ESR was > 5mm at baseline, it always de-
creased. 6/10 patients had an AJC of 0 following joint in-
jection and 4 of these 6 patients had follow-up JADAS
and cJADAS scores of less than or equal to 1 (consistent
with inactive disease or remission): no other patientshad JADAS/cJADAS scores indicating remission. Figure 3
illustrates that the parent global scores generally contrib-
uted more to the overall JADAS score than the AJC or
physician global score with no suggestion of a relation-
ship to ILAR subtype or disease duration.
Qualitative MRI reports
For the first MRI assessment, synovial thickening outside
normal limits was reported for six of the subjects at
baseline and reported within normal limits for five sub-
jects (Tables 1 and 2). Minimal synovial enhancement in
keeping within normal limits was noted in the report on
two of the latter subjects, and no enhancement noted on
the other three subjects. All reports for the second MRI
assessment found no synovial thickening beyond normal
limits. Chondral surfaces all appeared to be well main-
tained and there was no evidence of bone oedema.
Quantitative MRI measurements
The synovial volumes measured at baseline and at
follow-up are given in Table 2. Across the 10 subjects
who attended follow-up appointments the median
(IQR) synovial volume was reduced from 38.5 (82.1)
cm3 to 0.0 (0.2) cm3 (p = 0.005). There were three
signatures of synovial volume response. The first
group (n = 6) had frank synovitis, called qualitatively
by the radiologist as outside normal limits and with a
median synovial volume of 79.6cm3 (34.5cm3, Fig. 4).
On post-treatment follow-up, these volumes reduced
to a median of 0.0cm3 (0.6cm3). The second group
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Fig. 3 The JADAS scores for the subjects at baseline and follow-up MRI scanning. Column shading indicates the relative contribution of the four
JADAS components. The overall score is often dominated by the patient/parent global assessment, with no clear relationship to the physician
assessment. There was no follow-up data available for subject 2, and blood tests were not clinically indicated for subject 1 at baseline and
subjects 5 and 10 at follow-up. JADAS, juvenile arthritis disease activity score; IAGI, intra-articular glucocorticoid injection; ESR, erythrocyte
sedimentation rate
Bennett et al. Pediatric Rheumatology           (2019) 17:74 Page 7 of 12(n = 3) had a measurable synovial enhancement (with
volume > 1.0 cm3), were called within normal limits by
the radiologist and had a median synovial volume of
1.2cm3 (0.1cm3), which reduced to 0.0cm3 (0.1cm3)
post treatment. The remaining subject had aTable 2 Quantitative MRI results at baseline (B) and follow-up (F)
Subject Synovial volume
(cm3)
Maximum uptake
rate (%/s)
Signal
enhancement (%)
Radiol
beyon
B F B F B F B
1 25.7 0.0 1.5 0.0 116 0 Y
2 0.6 – 0.5 – 35 – N
3 1.2 0.0 0.4 0.0 57 0 N
4 51.2 0.1 1.8 0.4 148 109 Y
5 72.2 0.7 2.8 0.5 190 90 Y
6 0.1 0.0 0.0 0.0 10 6 N
7 92.2 0.0 6.7 0.0 225 0 Y
8 101.6 1.9 4.6 1.9 157 126 Y
9 87.0 0.0 7.1 0.0 228 0 Y
10 1.2 0.0 0.6 0.0 95 0 N
11 1.1 0.2 1.5 0.8 145 103 N
Median 38.5 0.0† 1.7 0.0$ 147 3† –
IQR 82.1 0.2 3.3 0.5 82 100 –
Baseline medians and IQRs (interquartile ranges) exclude subject 2 who was lost to
IAGI = repeat intra-articular glucocorticoid injection after follow-upnegligible initial volume which was unchanged post-
treatment (0.1cm3 vs. 0.0cm3) within the limits of
inter-observer reproducibility.
Both the median initial rate of contrast uptake and the
median signal enhancement for the 10 young peopleogist reports synovial enhancement
d normal limits (Y/N)
Clinician assessed disease activity
in injected knee (Y /N)
F B F
N Y Y (rpt IAGI)
– Y –
N Y N
N Y Y (rpt IAGI)
N Y N
N Y N
N Y N
N Y Y (rpt IAGI)
N Y N
N Y N
N Y N
–
–
follow-up. † p = 0.005, $ p = 0.008 at follow-up compared to baseline. Key: rpt
Fig. 4 Samples of difference images comparing measured synovial volume before and after IAGI. The difference images were derived from the
pre- and post-contrast T1-weighted FS TSE images to highlight the contrast uptake in the synovium for four subjects: (a) 12 year-old female
(25.7cm3 vs. 0.0cm3), (b) 11 year-old male (51.2cm3 vs. 0.1cm3), (c) 16 year-old female (72.7cm3 vs. 0.7cm3) and (d) 8 year-old male (101.6cm3 vs.
1.9cm3). The whole synovial volume is quoted in each case, not just for the slice shown. FS TSE, fat saturated turbo spin echo
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0.0%/s, p = 0.008, and 147 to 3%, p = 0.005 respectively
(Table 2 and Additional file 1).
Inter-observer agreement
Bland-Altman analysis for inter-observer agreement for
synovial volume showed no bias between observers
(− 0.04cm3, 95% limits of agreement 1.03cm3, p = n.s.),
negligible compared to the median volume of 38.5cm3.
The bias and 95% limits of agreement for the initial uptake
rate of contrast were 0.01%/s and 0.23%/s respectively,
while those for the signal enhancement were 2.7 and
12.9% respectively. The largest discrepancy in synovial vol-
ume between observers (1.9cm3) occurred in the largest
synovial volume measured (101.6cm3). All other differences
were below 0.6cm3. Inter-observer differences are very
small compared to the dynamic range of the intervention.
Correlation between clinical and radiological outcomes
There was a positive correlation between the pain global
score and the initial synovial volume (ρ = 0.67, p < 0.04).
There was no significant correlation between the de-
crease in synovial volume post-treatment and the change
in cJADAS, the change in global pain score, the parent
global score or the change in active joint count (regard-
less of whether the total joint count or the joint count
for the studied knee was used).
Feedback from the questionnaire and telephone
interview
Feedback from the questionnaire and telephone inter-
views was positive; all subjects reported that they would
recommend our research to their friends and families.Five core experiential themes emerged from the data en-
abling identification of five discrete recommendations
for paediatric MRI scanning (Table 3).
Discussion
We have demonstrated that quantitative MRI measure-
ments can be used to quantify synovial disease activity in
a stratified group of JIA patients undergoing IAGI. The
positive subject feedback shows that it is both feasible
and acceptable to collect quantitative MRI data in young
people aged 7–16 years with new-onset knee synovitis.
Six subjects had synovial hypertrophy outside radio-
logical standard limits at baseline with near-complete re-
duction in synovial volume at follow-up, an important
observation for using quantitative MRI in the context of
IAGI. Nine follow-up scans demonstrated significant re-
ductions in synovial volume, the initial rate of contrast
uptake and signal enhancement, demonstrating reduced
vascularity of the remaining synovium.
In six cases with post-treatment follow-up, no enhan-
cing synovial volume was detectable at follow-up while
four subjects had a small but detectable volume. Five
young people did not have synovial enhancement out-
side radiological reporting limits at baseline, similar to
the 49% of clinically active patients who did not have
synovitis according to JAMRIS classification in a qualita-
tive cross-sectional study [36]. Van Gulik et al. reported
normal MRI findings in 35% of patients with clinician-
defined knee synovitis [37]. In this study, quantitative
MRI was able to detect volume change post IAGI in 3/4
baseline scans falling below the standard reporting
threshold. 3/10 subjects had clinician-defined disease ac-
tivity at follow-up, though the MRI were reported within
Table 3 Themes and recommendations from the patient’s perspective. Five core themes relating to the patient experience
emerged from the data and from this we identified the following recommendations for paediatric MRI
Theme 1: Clear expectations
Knowing fully what to expect relaxes both the child and their family and helps alleviate any concerns or uncertainties.
Recommendations:
• Provide detailed information to alleviate any concerns or uncertainties both prior to the scan and on the day itself. This should include detailed
directions and guidance on what will happen on the day with enough information so the parent/carer can answer any questions the child may
have.
• Offer the opportunity to ask questions beforehand (e.g. telephone call from clinical team prior to appointment).
• Provide the opportunity to view scanner beforehand.
Theme 2: Creation of relaxing environment
Extra touches that make families feel at home help create a relaxing environment and create a more positive experience in which to have the scan.
Recommendations:
• Use trained paediatric staff to put both child and parent/carer at ease. Communication to be on a first name basis and whilst familiarity can add
an extra layer of relaxation, it is also acceptable to be simply introduced on the day.
• Use staff experienced in inserting cannulas in children to avoid extra stress that difficulties with their insertion can cause.
• Give the opportunity for child to listen to music of their choice during the scan.
• Give the option for parent/carer or member of staff to accompany child into scanner.
• Ensure pace of appointment is not rushed and is led by the child and parent/ carer’s needs.
• Care to be taken regarding scan setting wherever possible to reduce unnecessary concerns (e.g. having scan alongside cancer unit viewed as not
ideal).
Theme 3: Child centred approach
Scan experience can further be improved by adopting a child centred approach in which the child is seen as key and in control of the situation.
Recommendations:
• Direct discussion at child.
• Provide child friendly information leaflets as well as parent versions.
• Give the option for toys to distract child if required by child and parent/carer.
• Provide ‘completion certificate’ at the end and postcard in the post.
Theme 4: Increased understanding of the condition
An extra layer of positivity can be added to the experience by using the scan as a way to educate the families further about the child’s condition and
increase their understanding of what the scan is able to show.
Recommendations:
• Allow the opportunity to view images after the scan alongside detailed guidance on what the images show and where possible enable patients
to take a copy (e.g. photo) they can show other family members, friends or teachers at school.
Theme 5: Linking in to current treatment plan(s)
Effective management enabling linking into current treatment plans viewed positively by families.
Recommendations:
• Link in to current treatment plan wherever possible. For example providing the opportunity to take bloods at the same time as giving contrast
seen as useful especially since many children do not like needles.
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in two of these subjects. In retrospect, the negligible syn-
ovial volume for subject 6 suggests a non-synovial aeti-
ology to their symptoms, despite the clinical response to
IAGI.
Although the impact of IAGI on synovial volume and
vascularity was frequently dramatic, the quantitative
MRI changes were not always reflected in the composite
clinical assessments. Of the six children with no detect-
able synovial volume post IAGI (0.0cm3), only three
would be regarded as in remission according to cJADAS
(</=1), whilst one child with a post-treatment cJADAS
score of 0 had a measurable synovial volume. Our study
adds further weight to a growing concern that the
present definitions of remission may require reconsider-
ation in light of future imaging data [14].
The post-joint injection clinical assessments illustrate
that, in our cohort with low joint counts, the patient/
parent global scores contribute more to the JADASscore than the AJC/physician global score. This discrep-
ancy between family / physician perception of impact of
disease has been demonstrated previously [38] and our
study further highlights the risk of underestimating the
impact of oligoarthritis on everyday life.
There have been previous attempts to quantify syn-
ovial volume changes with treatment over similar time-
scales using quantitative MRI in JIA. Workie et al.
studied the 3-month response to treatment, though only
four subjects received IAGI at that time point [27], with
modest synovial volume reduction of 26% and 29% in
the initial uptake rate: the children recruited had a me-
dian of eight active joints at baseline.
A one-year follow-up of active wrist involvement in 36
children demonstrated a 50% reduction in synovial vol-
ume, though treatment types and durations were not
specified [39]. In other arthritides, such as rheumatoid
arthritis, more modest changes are reported with quanti-
tative methods [25, 39, 40].
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adds important information both to clinical assessments
and to current qualitative MRI reporting. We chose to
assess the impact of IAGI in new onset knee synovitis,
as knee synovitis is common. However, we anticipate
that quantitative MRI reporting may have more potential
in the assessment of disease activity in less accessible
joints and in the presence of long-standing disease, joint
damage or co-existing pain syndromes.
The limitations of our study include the small sample
size studied. Although the study was open to sequential eli-
gible families with young people aged 4–16 years, only one
child younger than 7 years was approached. The family de-
clined, citing concerns that their child may not lie still.
Therefore, we cannot draw conclusions about the accept-
ability of MRI in the youngest children. Contact with one
subject was lost before follow-up scanning, though their
responses to the questionnaire and telephone interview fol-
lowing the first MRI visit were positive. The post-IAGI
synovial volumes calculated in this study suggest that the
synovium of healthy knee joints has a negligible volume on
quantitative contrast-enhanced imaging. There are no
quantitative contrast-enhanced data on young people with
healthy knees: the closest study to date examined young
people with knee pain and non-inflammatory diagnoses
such as hypermobility and functional disorders [42].
The use of thresholding at defined signal enhancement
levels reduced subjective choice between the analysts,
with the decision dominating the analysis time (typically
20–30min per volume) being that of separating the
synovium from adjacent small blood vessels. These
vessels appeared to have a consistent small volume on
the pre- and post- IAGI imaging, so it may be possible
to evaluate the volume much faster, perhaps three mi-
nutes, with further development of the analysis software
and if the inclusion of minor vessels were to be toler-
ated, aiding clinical adoption. Translation to clinical
practice requires careful selection of the management
decisions in the clinical care pathway for which quantita-
tive MRI would be used, since MRI availability is limited.
These aspects are the subject of ongoing work.
This study focuses on the impact of IAGI in new-onset
knee synovitis, measured by quantitative MRI. Whilst the
near-complete resolution of knee synovitis post IAGI is an
interesting observation, the true value of quantitative MRI
techniques may be realised in future studies exploring the
impact of current treatment regimes on less accessible
joints such as the hip or temporomandibular joints and /
or comparing the relative efficacies of different therapeutic
regimes. Quantitative MRI has particular potential in
young people with oligoarticular disease in whom clinical
disease activity measures may not be sensitive or specific
enough to reliably identify changes in the degree of
localised synovial disease.Conclusions
This study has demonstrated that quantitative MRI can
measure the effect of IAGI on synovial volume and is
accessible and feasible for children aged between 7 and
16 years, with positive feedback from families. Synovial
volume was reduced markedly by IAGI, either to zero or
close to zero. Quantitative MRI provided different infor-
mation to traditional clinical disease activity measures
and was able to identify more patients with an improved
synovial volume than routine qualitative reporting. In
summary, quantitative MRI has the potential to add im-
portant information to our understanding of disease out-
comes in JIA.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12969-019-0377-7.
Additional file 1. Supplementary Methods, Supplementary Results,
Supplementary Fig. S1, Supplementary Fig. S2, Supplementary Table S1,
Supplementary References.Abbreviations
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